Zydus Lifesciences Ltd has bagged final approval from the US Food and Drug Administration (USFDA) to produce and market Dasatinib tablets in the US. The approved strengths are 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg.
Dasatinib is the generic version of Sprycel® tablets, a medication widely used for treating Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL). According to IQVIA MAT data (January 2025), Sprycel® tablets recorded annual sales of $1.81 billion in the US market.
The medication is primarily prescribed for:
Dasatinib tablets will be manufactured at Zydus’ Ahmedabad SEZ facility. With this latest approval, Zydus has now secured a total of 415 regulatory approvals from the USFDA. However, the company has also submitted 483 ANDAs since the FY 03-04 (as of December 31, 2024).
Shares of Zydus Lifesciences Ltd is currently trading at ₹906.40 which is a 2.14% gain than the previous close, The stock has witnessed a total of 5.76% dip in the last one year, and 10% dip in the last one year.
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.